Confirmatory factor analysis (CFA) was used to examine the structural validity of the SAAS.
Multiple-group CFA was used to determine if SAAS scores can be compared across patients with limited and diffuse disease subtypes. Cronbach's alpha was used to examine internal consistency reliability. Correlations of SAAS scores with measures of body image dissatisfaction, fear of negative evaluation, social anxiety, and depression were used to examine convergent validity. SAAS scores were hypothesized to be positively associated with all convergent validity measures, with all correlations significant and moderate to large in size.
Results: A total of 938 patients with SSc were included. CFA supported the one-factor structure (CFI: 0.92; SRMR: 0.04; RMSEA: 0.08), and multiple-group CFA indicated that the scalar invariance model best fit the data. Internal consistency reliability was good in the total sample, and in disease subgroups. Overall, evidence of convergent validity was found with measures of body image dissatisfaction, fear of negative evaluation, social anxiety, and depression.
Conclusion:
The SAAS can be reliably and validly used to assess fear of appearance evaluation in patients with SSc, and SAAS scores can be meaningfully compared across disease subtypes.
Significance and Innovations
 Changes in appearance are common in SSc and can result in significant body image dissatisfaction and appearance-related anxiety.
 The Social Appearance Anxiety Scale can be validly and reliably used to assess fear of appearance evaluation in patients with SSc.
 Social Appearance Anxiety Scale scores can be meaningfully compared across patients with limited and diffuse disease.
Systemic sclerosis (SSc), or scleroderma, is a chronic rheumatic disease characterized by thickening of the skin and internal organs (1) . Changes in appearance are common, and can include altered facial features, digital ulcers, hypo-and hyper-pigmentation, hand contractures, and telangiectasias (visible dilation of blood vessels beneath the skin). These changes can have significant psychosocial impacts as they may occur in socially-relevant areas such as the hands and face (2, 3) . There is no cure for the disease, and disfiguring appearance changes can be permanent. Given these appearance changes, body image dissatisfaction and appearance-related social discomfort are important concerns for patients with SSc (2, 3).
Social appearance anxiety, or a fear of situations in which one's appearance will be evaluated, may be particularly salient in SSc due to the changes in appearance that can occur, often in socially-relevant areas of the body. Despite the high rates of appearance concerns in SSc, research in appearance-related social anxiety is limited. A small number of studies have evaluated social discomfort due to appearance changes (2, 3) and fear of negative evaluation (4), but no studies have examined social appearance anxiety in patients with SSc. Social discomfort due to appearance changes refers to unease in social interactions because of appearance changes.
Fear or negative evaluation refers to worry about being evaluated unfavorably and can include concerns about appearance, but is not specific to appearance. A measure of social appearance anxiety validated in patients with SSc is needed to support research in this area. Since appearance anxiety may be associated with disease severity, such a measure would ideally have measurement equivalence across limited and diffuse disease subgroups. Diffuse SSc is associated with more skin involvement than limited SSc, and thus can be used as an indicator of severity, particularly related to appearance (1).
The Social Appearance Anxiety Scale (SAAS; 5) is a self-report measure that assesses fear of situations in which one's appearance will be evaluated. The SAAS has demonstrated strong measurement properties in various populations, such as university students (5-6), female eating disorder patients (7), and gay and bisexual men of color (8), but has not been validated in SSc. A unidimensional factor structure has been found in previous studies, and internal consistency reliability has been excellent (s: .93 to .96). Convergent validity has been demonstrated via significant, moderate to large correlations in the expected directions with measures of depression, anxiety, body image dissatisfaction, and fear of negative evaluation (5-
The first objective of the present study was to examine the factor structure of the SAAS in a sample of patients with SSc. A unidimensional factor structure was expected. The second objective was to examine the internal consistency reliability of the measure. Based on previous studies, internal consistency reliability was expected to be strong with measures of social discomfort, fear of negative evaluation, and social anxiety were expected to be more robust than correlations with depression and dissatisfaction with appearance. Items from the SAAS were developed consulting diagnostic symptoms of social anxiety disorder.
Thus, the SAAS was expected to be more strongly associated with discomfort in social contexts and anxiety as compared to clinical symptoms of depression and dissatisfaction with appearance, which is distinct from social discomfort (10) . The final objective was to determine if SAAS scores can be meaningfully compared across limited and diffuse subtypes.
Methods

Participants and procedures
This study was a cross-sectional analysis of baseline data of patients enrolled in the 
Patient Health Questionnaire-8 (PHQ-8; 13). The PHQ-8 measures depressive
symptoms over the last 2 weeks. Response options range from 0 (not at all) to 3 (nearly every day). Scores for each item are summed to produce a total score. Total scores range from 0 to 24 with higher scores indicating more depressive symptoms. Internal consistency reliability in the present study was good (α = 0.89). -6; 14) . The SIAS-6 is a 6-item measure that assesses anxiety resulting from social interactions. Response options range from 0 (not at all characteristic or true of me) to 4 (extremely characteristic or true of me). Total scores are computed by summing scores for all items, and range from 0 to 24. Higher scores indicate greater anxiety from social interactions. Internal consistency reliability was excellent (α = 0.90).
Social Interaction Anxiety Scale-6 (SIAS
Statistical Analysis
Descriptive statistics for demographic and medical variables were calculated for the total sample in SPSS version 22.0. Confirmatory factor analysis using maximum likelihood parameter estimates was used to examine the factor structure of the SAAS in Mplus version 7. 17) was used. A unidimensional factor structure was hypothesized to best fit the data. If a unidimensional factor structure did not fit the data well, modification indices would be examined in attempt to improve model fit. Once a factor structure with adequate fit was identified, multiple-group CFA was used to evaluate measurement invariance of the SAAS across limited and diffuse patients with SSc. For the multiple-group CFA, configural invariance, metric invariance, and scalar invariance models were iteratively examined. For the configural invariance model, a one-factor solution was fit to the data in two separate models, one each for the limited and diffuse SSc groups. All parameters were freely estimated. For the more restrictive metric invariance model, factor loadings were constrained to equivalence across disease subtypes. For the most restrictive scalar invariance model, factor loadings and item intercepts were constrained to equivalence across disease subtypes. The CFI was used to statistically compare increasingly restrictive models for the multiple-group CFA. A change in CFI of  .01
was indicative of no difference between nested models (18).
Internal consistency reliability was examined using Cronbach's coefficient alpha. 
Convergent validity was examined via
Results
Descriptive Statistics
Sample statistics are reported in Table 1 . Of 1,012 patients who initiated baseline assessments, forty-seven patients were removed from the sample because they did not complete any items of the SAAS, and one patient was removed because one item was not completed. In addition, patients with sine (n = 18) or unknown disease subtype (n = 8) were not included.
Participants included in analyses (N = 938) were predominantly female (88 %), married (68%), and had a mean age of 55.6 years. The mean time since the onset of the first non-Raynaud's symptom was 11.8 years (SD = 8.9). The mean SAAS score in the total sample was 28.3 (SD = 13.2). SAAS scores significantly differed across limited (M = 26.5, SD = 11.9) and diffuse (M = 30.6, SD = 14.4) disease subtype.
Confirmatory Factor Analysis
Results from the CFA supported the hypothesized one-factor model in the total sample ( Table 2 ). The one-factor model fit well based on three descriptive fit indices (CFI: 0.92; SRMR:
0.04; RMSEA: 0.08; S-Bχ 2 = 678.37, p < .01). All factor loadings were significant, and all factor loadings ranged from .64 to .90 with the exception of item 1 (.43). 
Multiple-group Confirmatory
Internal Consistency Reliability and Convergent Validity
Internal consistency reliability was excellent for the total sample (α = 0.96) and for limited (α = 0.96) and diffuse (α = 0.97) disease subtypes. Correlations with convergent validity measures are shown in Table 3. SAAS scores Correlations with the SIAS-6 and PHQ-8 were significantly higher than with the Brief-SWAP Dissatisfaction with Appearance subscale, but there were no significant differences between SIAS-6 and PHQ-8 correlation coefficients.
Discussion
The results of the present study demonstrate that the SAAS is a valid and reliable measure for use with SSc patients. Confirmatory factor analyses provided support for the scalar invariance model, indicating a unidimensional factor structure of the measure for all patients with SSc, and across diffuse and limited SSc subtypes. Item 1 had a substantially lower factor loading than other items, but this is consistent with previous studies (5, (7) (8) . This is likely because of the positive phrasing of the item, as all other items are negatively worded. Internal consistency reliability was excellent. Overall, evidence of convergent validity was found.
Correlations between the SAAS and measures of social discomfort, fear of negative evaluation, social anxiety, and symptoms of depression were large, whereas the correlation with a measure of dissatisfaction with appearance was only moderate. Although the correlation with depressive symptoms was slightly larger than hypothesized, the most robust correlations were with social discomfort related to body image dissatisfaction and fear of negative evaluation, followed by social anxiety, symptoms of depression, and dissatisfaction with appearance. This suggests that SAAS scores are more closely associated with social discomfort as compared to more broad clinical symptoms of psychological distress and dismay about appearance.
There are limitations to this study. The SPIN Cohort is a convenience sample of patients receiving treatment at SPIN recruiting centers. Patients completed study questionnaires online, potentially limiting the generalizability of study findings. Because data are cross-sectional, stability (via test-retest reliability) and sensitivity to change of scores on the SAAS could not be examined.
In sum, findings from the present study suggest that the SAAS can be reliably and validly used to assess fear of appearance evaluation in patients with limited and diffuse SSc, and that SAAS scores can be meaningfully compared across disease subtype. Note. SSc = systemic sclerosis; mRss = modified Rodnan skin score; SAAS = Social Appearance Anxiety Scale; SWAP = Satisfaction with Appearance Scale; PHQ-8 = Patient Health Questionnaire-8; SIAS=6 = Social Interaction Anxiety Scale; BFNE-II = Brief Fear of Negative Evaluation Scale-II. Note. For all factor loadings p < .05. Note. Values are presented as r. All correlations were significant at p < .05 (two-tailed). SAAS = Social Appearance Anxiety Scale; SWAP = Satisfaction with Appearance Scale; PHQ-8 = Patient Health Questionnaire-8; SIAS=6 = Social Interaction Anxiety Scale; BFNE-II = Brief
Fear of Negative Evaluation Scale-II.
